Ovarian cancer is one of the three major malignant tumors in gynecology. Its incidence ranks 3rd among malignant tumors of the female reproductive tract, but its mortality rate ranks first. Statistics show that 20% to 25% of ovarian cancer cases have a family history, and women whose mothers or sisters have ovarian cancer are 18 times more likely to develop ovarian cancer than women without a similar history! Only 20%-30% of patients with advanced ovarian cancer can survive for 5 years, while up to 80%-90% of patients with early stage ovarian cancer can survive for 5 years, with fast recovery and low recurrence rate after surgery, and some patients can get married and have children normally. Therefore, early diagnosis of ovarian cancer has always been one of the goals that gynecologic oncologists have been striving for. But unfortunately until today, no method has been found that can really achieve early diagnosis and facilitate clinical application. Cancer screening, i.e., the application of some method to perform regular testing on a large scale in the population for early detection, is one of the methods that can be considered for the early diagnosis of many cancers. Screening for cervical lesions has already yielded very promising results in reducing the incidence and mortality of cervical cancer. With this in mind, several clinical trials for ovarian cancer screening have been conducted internationally, but none have been very successful to date. The reasons for this are, on the one hand, that the population selected is not a real high-risk group, and on the other hand, the methods used are not reasonable or inefficient. The Gynecologic Oncology Center of Peking University People’s Hospital, after an in-depth study of international positive and negative experiences and combining the results of its own research for many years, has designed a new screening method and protocol for ovarian cancer high-risk groups. The protocol is based on the dynamic changes of the two most valuable and commonly used markers for ovarian cancer, CA125 and HE4, brought into a pre-derived mathematical model for calculation, and the resulting values can potentially predict the risk of developing ovarian cancer. Based on the low, intermediate and high risk groups, the corresponding clinical measures will be validated to establish a realistic and relatively cost-effective way to diagnose ovarian cancer at an early stage. The screening program has been approved by the relevant authorities and has received funding support from the Beijing Municipal Science Committee, and has been officially launched. Voluntary participants only need to undergo regular venipuncture for a small amount of blood, which is minimally invasive and all free of charge.